Boehringer Ingelheim registers Phase Ib/II trial testing obrixtamig plus pumitamig in SCLC
New registry entry details a combination study in extensive-stage small cell lung cancer sponsored by Boehringer Ingelheim with BioNTech SE as collaborator.
One new trial entry appeared for Boehringer Ingelheim this week.
- NCT07843940 is a Phase Ib/II trial testing obrixtamig (BI 764532) in combination with pumitamig (BNT327), with and without chemotherapy, in extensive-stage small cell lung carcinoma. The lead sponsor is Boehringer Ingelheim, with BioNTech SE listed as a collaborator.1 The study is recruiting, with an estimated enrollment of 55 participants1 and an estimated primary completion date of 2030-04-171. The purpose is to assess how well patients tolerate the combination and whether it can shrink tumors.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.